目的 探讨祖卡木颗粒联合利巴韦林治疗小儿急性上呼吸道感染的临床有效性和安全性。方法 选取2016年3月—2017年3月在荆州市中医院就诊的小儿急性上呼吸道感染患儿141例，根据用药不同将患儿分成对照组（70例）和治疗组（71例）。对照组患儿静脉滴注利巴韦林注射液，10 mg/kg加入生理盐水稀释成1 mg/mL滴注，2次/d。治疗组患儿在对照组基础上口服祖卡木颗粒，1袋/次，3次/d。两组患儿均连续治疗5 d。观察两组患儿临床疗效，同时比较治疗前后两组患者临床症状消失时间、血清淀粉样蛋白A（SAA）、白细胞计数（WBC）、超敏C反应蛋白（hs-CRP）水平及不良反应情况。结果 治疗后，对照组和治疗组患儿临床有效率分别为85.71%和97.18%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组患儿体温恢复、咳嗽消失和咽喉红肿消失时间均明显早于对照组（P<0.05）。治疗后，两组患儿血清SAA和hs-CRP水平均明显降低（P<0.05），WBC水平明显升高（P<0.05），且治疗组患儿血清SAA、hs-CRP和WBC水平明显优于对照组（P<0.05）。治疗期间，治疗组患儿不良反应发生率为4.23%，明显低于对照组的15.71%，两组比较差异具有统计学意义（P<0.05）。结论 祖卡木颗粒联合利巴韦林治疗小儿急性上呼吸道感染临床疗效好、安全性高，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy and safety of Zukamu Granules combined with ribavirin in treatment of acute upper pespiratory tract infection in children. Methods Children (144 cases) with acute upper pespiratory tract infection in Jingzhou Hospital of Traditional Chinese Medicine from March 2016 to March 2017 were divided into control (70 cases) and treatment (71 cases) groups based on different treatments. Children in the control group were iv administered with Ribavirin Injection, 10 mg/kg added into normal saline and dilution into 1 mg/mL, twice daily. Children in the treatment group were po administered with Zukamu Granules on the basis of the control group, 1 bag/time, three times daily. Children in two groups were treated for 5 d. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptom, the serum SAA, WBC and hs-CRP levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 85.71% and 97.18% respectively, and there were differences between two groups (P<0.05). After treatment, the fever clearance time, the disappearance time of cough and pharyngitis in the treatment group was significantly earlier than that in the control group (P<0.05). After treatment, the serum SAA and hs-CRP levels in two groups were significantly decreased (P<0.05), but WBC levels were significantly increased (P<0.05), and the SAA, hs-CRP and WBC levels in the treatment group were significantly better than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 4.23%, which was significantly lower than 15.71% in the control group, with significant difference between two groups (P<0.05). Conclusion Zukamu Granules combined with ribavirin in treatment of acute upper pespiratory tract infection in children is clinically effective and safe, which has a certain clinical application value.